Navigation Links
InspireMD Reports Financial Results For Period Ended March 31, 2013
Date:5/8/2013

BOSTON and TEL AVIV, Israel, May 8, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financial results for the three month period ended March 31, 2013, the third quarter of its 2013 fiscal year.

Revenue for the period increased by 33% over the March 31, 2012 quarter, reflecting the impact of several new marketing initiatives leveraging positive validation from the MASTER I trial of the Company's MGuard™ Embolic Protection Stent (EPS™) published in the November 6, 2012 edition of the peer-reviewed Journal of American College of Cardiology (JACC), Vol. 60, No. 19. Authors of the study concluded that, "among patients with acute STEMI (ST Segment Elevation Myocardial Infarction) undergoing emergent PCI enrolled in the present multicenter, randomized, controlled trial, the MGuard Embolic Protection Stent (EPS) compared to standard metallic stents resulted in superior rates of epicardial coronary flow and complete STR, with trends present toward reduced microvascular obstruction, infarct size and mortality."

Alan Milinazzo, President and CEO of InspireMD, said, "Since joining the Company on January 3rd, we have made significant progress in key strategic areas of the business. In addition to a solid increase in quarterly revenues, we obtained the CE Mark for our carotid stent and we strengthened our board and executive management team. Momentum continued in April as we re-capitalized the Company, uplisted to the NYSE MKT and received regulatory approval to begin enrolling patients in our MASTER II clinical trial. These achievements represent a very good start to 2013 and we expect to continue to deliver strong results on multiple fronts throughout the year."

Financial Highlights for the Quarter Ended March 31, 2013--Revenue for the quarter ended March 31, 2013 totaled $1.5 million, an increase of 33% over the $1.1 million re
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
2. InspireMD Closes $25 Million Underwritten Public Offering
3. InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
4. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
5. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
6. InspireMD Reports Results for Period Ended Dec. 31, 2012
7. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
8. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
9. InspireMD Reports Results For Period Ending Sept. 30, 2012
10. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
11. InspireMD to Present at Harvard Investors Group on June 27 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... - New Hayfever Relief Product Based on Acupressure ... , - With Photo , ... it,s believed that,it now affects as many as 1 in 4 ... either complete misery with symptoms such as reduced,concentration, runny nose and ...
... Improvement Firm Recognizes Efforts in Patient SatisfactionSOUTH BEND, Ind., ... Press Ganey Associates, Inc., is proud to recognize all ... improving the quality of care they provide."The doctors, nurses, ... to improve quality, and they deserve to be commended," ...
... urged to prevent head, neck injuries , , SUNDAY, May ... help prevent head and neck injuries related to recreational ... year in the United States, about 1.5 million people ... and nearly 12,000 are treated for neck fractures, according ...
... Support the Nancy Davis Foundation for Multiple Sclerosis LOS ... the world,s most exclusive super sport cars, donated the ... to support the Nancy Davis Foundation for Multiple Sclerosis ... charity event at the Hyatt Regency Century Plaza in ...
... thwart hospital ,superbugs, viruses and mold, scientists say ... paint kills disease-causing bacteria, mold, fungi and viruses, said ... claim their paint, which can be used in homes, ... so-called "superbugs," antibiotic-resistant microbes that are found in hospitals ...
... free workshops with an emphasis on smoking cessation to raise public ... in order to improve their quality of life. , ... ... consecutive year, May 2009 has been designated Stroke Awareness Month. During ...
Cached Medicine News:Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 2Health News:'Qu-Chi' Acupressure Band Gives Hayfever Misery the Elbow 3Health News:Press Ganey Supports National Hospital Week 2Health News:Press Ganey Supports National Hospital Week 3Health News:Ladders, Swings and More Can Cause Peril 2Health News:First U.S. Lamborghini Gallardo LP 560-4 Spyder Auctioned at Race to Erase MS Charity Event 2Health News:Health Care Professionals Offer Free Consultations for National Stroke Awareness Month 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Finesse II electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
... 950, the first High Frequency Desiccator with Cut. ... half of the unit is a high frequency ... popular Aaron 900. The other half is a ... power and coag capabilities plenty of power ...
Medicine Products: